Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 9, 2009 - Issue 8
Submit an article Journal homepage
90
Views
9
CrossRef citations to date
0
Altmetric
Review

Update on genetic predisposition to breast cancer

Munaza Ahmed Department of Genetic Medicine, St Mary’s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Oxford Road, Manchester, M13 9WL, UK. [email protected]
,
Fiona Lalloo Department of Genetic Medicine, St Mary’s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Oxford Road, Manchester, M13 9WL, UK. [email protected]
&
D Gareth Evans Department of Genetic Medicine, St Mary’s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Oxford Road, Manchester, M13 9WL, UK. [email protected]
Pages 1103-1113 | Published online: 10 Jan 2014

References

  • McIntosh A, Shaw C, Evans G et al. Clinical guidelines and evidence review for the classification and care of women at risk of familial breast cancer. NICE Guideline CG014 (2004).
  • Broca P. Traite des Tumeurs. [Asselin]. Paris (1866).
  • Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am. J. Hum. Genet.48(2), 232–242 (1991).
  • Anderson DE, Badzioch MD. Familial breast cancer risks: effects of prostate and other cancers. Cancer72(1), 114–119 (1993).
  • Peto J, Mack TM. High constant incidence in twins and other relatives of women with breast cancer. Nat. Genet.26(4), 411–414 (2000).
  • Peto J, Collins N, Barfoot R et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J. Natl Cancer Inst.91(11), 943–949 (1999).
  • Neuhausen SL, Marshall CJ. Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. Cancer Res.54(23), 6069–6072 (1994).
  • Collins N, McManus R, Wooster R et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12–13. Oncogene10(8), 1673–1675 (1995).
  • Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br. J. Cancer83(10), 1301–1308 (2000).
  • Thompson D, Easton DF. Cancer incidence in BRCA1 mutation carriers. J. Natl Cancer Inst.94(18), 1358–1365 (2002).
  • Hall JM, Lee MK, Newman B et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science250(4988), 1684–1689 (1990).
  • Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science266(5182), 66–71 (1994).
  • Boulton SJ. Cellular functions of the BRCA tumour-suppressor proteins. Biochem. Soc. Trans.34(Pt 5), 633–645 (2006).
  • Eyfjord JE, Bodvarsdottir SK. Genomic instability and cancer: networks involved in response to DNA damage. Mutat. Res.592(1–2), 18–28 (2005).
  • Simard J, Tonin P, Durocher F et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat. Genet.8(4), 392–398 (1994)
  • Mazoyer S. Genomic rearrangements in the BRCA1 and BRCA2 genes. Hum. Mutat.25(5), 415–422 (2005).
  • Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers: Breast Cancer Linkage Consortium. Am. J. Hum. Genet.56(1), 265–271 (1995).
  • Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet.72(5), 1117–1130 (2003).
  • Evans DG, Shenton A, Woodward E et al. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer8, 155(2008).
  • Brose MS, Rebbeck TR, Calzone KA et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J. Natl Cancer Inst.94(18), 1365–1372 (2002).
  • Stratton MR, Ford D, Neuhasen S et al. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat. Genet.7(1), 103–107 (1994).
  • Friedman LS, Gayther SA, Kurosaki T et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am. J. Hum. Genet.60(2), 313–319 (1997).
  • Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet.62(3), 676–689 (1998).
  • Tai YC, Domchek S, Parmigiani G et al. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J. Natl Cancer Inst.99(23), 1811–1814 (2007).
  • Breast cancer linkage consortium.: pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases: Breast Cancer Linkage Consortium. Lancet349(9064), 1505–1510 (1997).
  • Lakhani SR. The pathology of hereditary breast cancer. Dis. Markers15(1–3), 113–114 (1999).
  • Lakhani SR, Van De Vijver MJ, Jacquemier J et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol.20(9), 2310–2318 (2002).
  • Foulkes WD, Stefansson IM, Chappuis PO et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl Cancer Inst.95(19), 1482–1485 (2003).
  • Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA100(14), 8418–8423 (2003).
  • Easton DF, Bishop DT, Ford D et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet.52(4), 678–701 (1993).
  • Wooster R, Neuhausen SL, Mangion J et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. Science265(5181), 2088–2090 (1994).
  • Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature378(6559), 789–792 (1995).
  • Tavtigian SV, Simard J, Rommens J et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat. Genet.12(3), 333–337 (1996).
  • Thorslund T, West SC. BRCA2: a universal recombinase regulator. Oncogene26(56), 7720–7730 (2007).
  • Roa BB, Boyd AA, Volcik K et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat. Genet.14(2), 185–187 (1996).
  • Thorlacius S, Olafsdottir G, Tryggvadottir L et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat. Genet.13(1), 117–119 (1996).
  • Johannesdottir G, Gudmundsson J, Bergthorsson JT et al. High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res.56(16), 3663–3665 (1996).
  • Gayther SA, Mangion J, Russell P et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat. Genet.15(1), 103–105 (1997).
  • Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am. J. Hum. Genet.68(2), 410–419 (2001).
  • Evans DG, Bulman M, Young K et al. BRCA1/2 mutation analysis in male breast cancer families from North West England. Fam. Cancer7(2), 113–117 (2008).
  • The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers.The Breast Cancer Linkage Consortium. J. Natl Cancer Inst.91(15), 1310–1316 (1999).
  • Howlett NG, Taniguchi T, Olson S et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science297(5581), 606–609 (2002).
  • Taniguchi T, D’Andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress. Blood107(11), 4223–4233 (2006).
  • Reid S, Renwick A, Seal S et al. Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. J. Med. Genet.42(2), 147–151 (2005).
  • Malkin D, Li FP, Strong LC et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science250(4985), 1233–1238 (1990).
  • Srivastava S, Zou ZQ, Pirollo K et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature348(6303), 747–749 (1990).
  • Garber JE, Goldstein AM, Kantor AF et al. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res.51(22), 6094–6097 (1991).
  • Liaw D, Marsh DJ, Li J et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet.16(1), 64–67 (1997).
  • Hearle N, Schumacher V, Menko FH et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin. Cancer Res.12(10), 3209–3215 (2006).
  • Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology121(6), 1348–1353 (2001).
  • Smith P, McGuffog L, Easton DF et al. A genome wide linkage search for breast cancer susceptibility genes: genes chromosomes Cancer45(7), 646–655 (2006).
  • Antoniou AC, Pharoah PD, McMullan G et al. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet. Epidemiol.21(1), 1–18 (2001).
  • Meijers-Heijboer H, van den OA, Klijn J et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet.31(1), 55–59 (2002).
  • Ahn J, Urist M, Prives C. The Chk2 protein kinase. DNA Repair (Amst.)3(8–9), 1039–1047 (2004).
  • Swift M, Reitnauer PJ, Morrell D et al. Breast and other cancers in families with ataxia-telangiectasia. N. Engl. J. Med.316(21), 1289–1294 (1987).
  • Gatti RA, Berkel I, Boder E et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22–23. Nature336(6199), 577–580 (1988).
  • Savitsky K, Bar-Shira A, Gilad S et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science268(5218), 1749–1753 (1995).
  • Shiloh Y. The ATM-mediated DNA-damage response: taking shape. Trends Biochem. Sci.31(7), 402–410 (2006).
  • Renwick A, Thompson D, Seal S et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat. Genet.38(8), 873–875 (2006).
  • Cantor SB, Bell DW, Ganesan S et al. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell105(1), 149–160 (2001).
  • Peng M, Litman R, Jin Z et al. BACH1 is a DNA repair protein supporting BRCA1 damage response. Oncogene25(15), 2245–2253 (2006).
  • Seal S, Thompson D, Renwick A et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat. Genet.38(11), 1239–1241 (2006).
  • Levitus M, Waisfisz Q, Godthelp BC et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat. Genet.37(9), 934–935 (2005).
  • Rahman N, Seal S, Thompson D et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat. Genet.39(2), 165–167 (2007).
  • Reid S, Schindler D, Hanenberg H et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat. Genet.39(2), 162–164 (2007).
  • Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat. Genet.40(1), 17–22 (2008).
  • Heikkinen K, Rapakko K, Karppinen SM et al. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis27(8), 1593–1599 (2006).
  • Tommiska J, Seal S, Renwick A et al. Evaluation of RAD50 in familial breast cancer predisposition. Int. J. Cancer118(11), 2911–2916 (2006).
  • Smith A, Moran A, Boyd MC et al. Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. J. Med. Genet.44(1), 10–15 (2007).
  • Breast Cancer Association Consortium. Commonly studied single-nucleotide polymorphisms and breast cancer: Results from the Breast Cancer Association Consortium. J. Natl Cancer Inst.98(19), 1382–1396 (2006).
  • Stacey SN, Manolescu A, Sulem P et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet.39(7), 865–869 (2007).
  • Hunter DJ, Kraft P, Jacobs KB et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet.39(7), 870–874 (2007).
  • Easton DF, Pooley KA, Dunning AM et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature447(7148), 1087–1093 (2007).
  • Cox A, Dunning AM, Garcia-Closas M et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat. Genet.39(3), 352–358 (2007).
  • Gold B, Kirchhoff T, Stefanov S et al. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc. Natl Acad. Sci. USA105(11), 4340–4345 (2008).
  • Stacey SN, Manolescu A, Sulem P et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet.40(6), 703–706 (2008).
  • Zheng W, Long J, Gao YT et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat. Genet.41(3), 324–328 (2009).
  • Fletcher O, Johnson N, Gibson L et al. Association of genetic variants at 8q24 with breast cancer risk. Cancer Epidemiol. Biomarkers Prev.17(3), 702–705 (2008).
  • Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin. Cancer Res.14(24), 8000–8009 (2008).
  • Meyer KB, Maia AT, O’Reilly M et al. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol.6(5), e108(2008).
  • Domchek SM, Weber BL. Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene25(43), 5825–5831 (2006).
  • Pharoah PD, Antoniou AC, Easton DF et al. Polygenes, risk prediction, and targeted prevention of breast cancer. N. Engl. J. Med.358(26), 2796–2803 (2008).
  • Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell108(2), 171–182 (2002).
  • Kennedy RD, Quinn JE, Mullan PB et al. The role of BRCA1 in the cellular response to chemotherapy. J. Natl Cancer Inst.96(22), 1659–1668 (2004).
  • Lakhani SR, Reis-Filho JS, Fulford L et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin. Cancer Res.11(14), 5175–5180 (2005).
  • Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature434(7035), 917–921 (2005).
  • Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med.361(2) 123–134 (2009).
  • Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J. Natl Cancer Inst.77(1), 89–92 (1986).
  • Mathew CG. Fanconi anaemia genes and susceptibility to cancer. Oncogene25(43), 5875–5884 (2006).
  • Antoniou AC, Spurdle AB, Sinilnikova OM et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am. J. Hum. Genet.82(4), 937–948 (2008).
  • Antoniou AC, Sinilnikova OM, Simard J et al. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am. J. Hum. Genet.81(6), 1186–1200 (2007).
  • Hughes DJ. Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Fam. Cancer7(3), 233–244 (2008).
  • Brohet RM, Goldgar DE, Easton DF et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J. Clin. Oncol.25(25), 3831–3836 (2007).
  • Chang-Claude J, Andrieu N, Rookus M et al. Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol. Biomarkers Prev.16(4), 740–746 (2007).
  • Mitchell G, Antoniou AC, Warren R et al. Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Res.66(3), 1866–1872 (2006).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.